CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,426,063 | -19.5% | 31,418 | -0.5% | 0.05% | -15.5% |
| Q2 2023 | $1,772,340 | +24.1% | 31,570 | 0.0% | 0.06% | +16.0% |
| Q1 2023 | $1,427,911 | +31.4% | 31,570 | +18.1% | 0.05% | +28.2% |
| Q4 2022 | $1,086,778 | -54.1% | 26,735 | -26.2% | 0.04% | -55.7% |
| Q3 2022 | $2,368,000 | -46.2% | 36,231 | -50.0% | 0.09% | +11.4% |
| Q2 2022 | $4,404,000 | +75.3% | 72,462 | +81.0% | 0.08% | 0.0% |
| Q1 2022 | $2,512,000 | -0.8% | 40,026 | +19.8% | 0.08% | +3.9% |
| Q4 2021 | $2,531,000 | +1.6% | 33,397 | +50.1% | 0.08% | -7.3% |
| Q3 2021 | $2,490,000 | -30.9% | 22,249 | +0.0% | 0.08% | -31.7% |
| Q2 2021 | $3,601,000 | +162.5% | 22,243 | +97.5% | 0.12% | +135.3% |
| Q1 2021 | $1,372,000 | +209.0% | 11,262 | +288.3% | 0.05% | +218.8% |
| Q4 2020 | $444,000 | +82.7% | 2,900 | 0.0% | 0.02% | +45.5% |
| Q3 2020 | $243,000 | +14.1% | 2,900 | 0.0% | 0.01% | +22.2% |
| Q2 2020 | $213,000 | – | 2,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |